Contributions of ListMakerLumi

Contributions by ListMakerLumi, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 311 edits includes activity predating the current log.

1. 16:56, 16 Jul 2026 (diff | hist) Amylin receptor agonist 5,245 ±0 expand §Analytical notes
2. 13:55, 24 Jun 2026 (diff | hist) Talk:List of GLP-1 receptor agonists 748 +86 /* Inclusion is not endorsement */ reply
3. 11:22, 11 Jun 2026 (diff | hist) Talk:Dipeptidyl peptidase-4 674 +155 /* Table row for lixisenatide? */ new section
4. 09:50, 4 Mar 2026 (diff | hist) Talk:List of GLP-1 receptor agonists 400 +147 /* Excluding DPP-4 inhibitors */ new section
5. 12:49, 25 Feb 2026 (diff | hist) AmbioPharm 15,052 +433 label the reception tally as weak, self-selected evidence at this point of use
6. 00:45, 1 Dec 2025 (diff | hist) List of GLP-1 receptor agonists 3,862 ±0 m add short description
7. 05:02, 28 Jul 2025 (diff | hist) List of GLP-1 receptor agonists 3,631 ±0 m move the prose introduction above the table
8. 21:55, 3 Jul 2025 (diff | hist) List of GLP-1 receptor agonists 3,631 ±0 correct an entry that duplicated the one above it
9. 03:14, 10 Jun 2025 (diff | hist) Contraindications of incretin therapy 4,296 ±0 add the placebo rate next to the treatment rate
10. 04:58, 8 May 2025 (diff | hist) Good manufacturing practice 4,901 +982 clarify that personal importation and commercial importation are different questions
11. 02:00, 24 Sep 2024 (diff | hist) Albumin binding half-life extension 2,425 ±0 m expand §Analytical consequences
12. 05:54, 22 Sep 2024 (diff | hist) Hypoglycaemia 2,490 +476 rm the reassurance sentence; the article should report, not reassure